Australia Biosimulation Market (2026-2031)
The Australia Biosimulation Market was valued at $29.6 Million in 2026 and projected to reach to $46.3 Million by 2031, representing a compound annual growth rate of 16.2%. Australia's biosimulation market is poised for substantial growth as pharmaceutical companies and contract research organizations increasingly leverage computational modeling to accelerate drug development timelines and reduce costs.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Australia Biosimulation Market Trends and Insights
- This 16.2% compound annual growth rate reflects Brazil's increasing adoption of computational modeling technologies in pharmaceutical development and clinical research.
- Brazil is positioning itself as a key player in Latin America's digital health transformation, driven by rising investments in healthcare infrastructure and regulatory modernization. The biosimulation sector in Brazil benefits from growing collaboration between academic institutions, pharmaceutical companies, and government health agencies.
- Brazil's expanding biopharmaceutical industry and emphasis on precision medicine are accelerating demand for simulation-based drug development tools.
- By 2031, Brazil is expected to capture significant market share within the Latin American region, supported by improved access to advanced computational platforms and increased awareness of biosimulation's cost-saving potential. Brazil's market growth is underpinned by regulatory incentives and the country's commitment to reducing clinical trial timelines and development costs.
- As Brazil continues to strengthen its position in global pharmaceutical innovation, biosimulation adoption is anticipated to become integral to the country's drug discovery and development ecosystem..
Key Market Statistics
- CAGR (2026-2031) 16.2% CAGR
- Market Size, 2026 ~USD 29.6 Million
- Forecast, 2031 ~USD 46.3 Million
- Country Australia
Australia Biosimulation Market Overview
Market Valuation :
Australia's biosimulation market is valued at USD 29.6 million in 2026, demonstrating significant investment in computational drug development and modeling technologies across the region.
Strong Growth Trajectory :
With a CAGR of 16.2% through 2031, Australia's biosimulation market is expanding faster than many developed markets, driven by increased R&D spending and adoption of digital health solutions.
Projected Market Expansion :
The market is forecasted to reach USD 46.3 million by 2031, representing a 56% increase over the five-year period as pharmaceutical companies and research institutions embrace computational modeling.
Regional Leadership :
Australia is emerging as a key hub for biosimulation adoption in the Asia-Pacific region, supported by advanced healthcare infrastructure, regulatory support, and strong biotech innovation ecosystems.
Australia Biosimulation Market Dynamics
- The adoption of in silico technologies is being driven by regulatory incentives, growing collaboration between academic institutions and industry, and Australia's commitment to digital health innovation.
- Government initiatives supporting biotech advancement and the presence of world-class research facilities are creating favorable conditions for market expansion.
- By 2031, biosimulation is expected to become integral to Australia's drug development pipeline, positioning the country as a regional leader in computational pharmaceuticals and personalized medicine applications..
Related Ecosystem
Healthcare It
- Computed Tomography (CT)
- Machine Learning
- Magnetic Resonance Imaging (MRI)
- Natural Language Processing (NLP)
- Predictive Analytics
- CERNER CORPORATION
- PHILIPS HEALTHCARE
- Oracle Corporation
- GE HealthCare Technologies Inc.
- Siemens healthineers
Key Takeaways
- Brazil's biosimulation market is valued at USD 29.6 million in 2026 and is forecast to reach USD 46.3 million by 2031, representing a 16.2% CAGR.
- Brazil is leveraging biosimulation to accelerate drug development timelines and reduce clinical trial costs in its expanding biopharmaceutical sector.
- Growing partnerships between Brazilian academic institutions and pharmaceutical companies are driving adoption of computational modeling technologies.
- Brazil's regulatory modernization and government support for precision medicine initiatives are key catalysts for biosimulation market expansion through 2031.
Biosimulation Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | INDIA (Application) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 16.7% from 2026 to 2031 |
| Largest Segment | CONSULTING & ADVISORY (Offering) |
| Market Size Base Year (Billions) | ~USD 4.27 (2026) |
| Revenue Forecast (Billions) | ~USD 9.24 (2031) |
| Segments Covered | Type, Application, Therapeutic Area, Revenue Model, Deployment Model, End User, Offering |
Australia Biosimulation Market Report Segmentation
7 segment dimensions are covered across the global market.
By Type
- Adme/Toxicology
- Clinical Trial Simulation Software
- Clinical Trials
- Consulting & Advisory
- Data Analysis & Interpretation
- Demand Forecasting & Inventory Management
- Implementation, Training, And Support
- Integrated Software Suites/Platforms
- Lead Identification & Optimization
- Molecular Modeling & Simulation Software
- Other Biosimulation Software
- Other Manufacturing & Supply Chain Management Applications
- Pbpk Modeling & Simulation Software
- Phase I
- Phase Ii
- Phase Iii
- Phase Iv/Post-Marketing Surveillance
- Pk/Pd
- Pk/Pd Modeling & Simulation Software
- Preclinical Testing
- Production Planning & Optimization
- Quality Control & Process Monitoring
- Risk Management & Contingency Planning
- Standalone Modules
- Target Identification & Validation
- Toxicity Prediction Software
By Application
- Disease Modeling
- Drug Development
- Drug Discovery
- Manufacturing & Supply Chain Management
- Other Applications
By Therapeutic Area
- Cardiovascular Diseases
- Infectious Diseases
- Neurological Disorders
- Oncology
- Other Therapeutic Areas
By Revenue Model
- License-Based Models
- Pay-Per-Use Models
- Service-Based Models
- Subscription-Based Models
By Deployment Model
- Cloud-Based Models
- Hybrid Models
- On-Premise Models
By End User
- Academic & Research Institutions
- Contract Research Organizations
- Other End Users
- Pharmaceutical & Biotechnology Companies
- Regulatory Bodies
By Offering
- Services
- Software
Target Audience
- Pharmaceutical Companies : Need market intelligence to guide R&D investment decisions, assess competitive positioning, and identify opportunities to integrate biosimulation into drug development pipelines in Australia.
- Contract Research Organizations (CROs) : Require detailed market data to evaluate service expansion opportunities, benchmark capabilities against competitors, and develop biosimulation service offerings for Australian clients.
- Biotech & Software Vendors : Seek market insights to understand demand for biosimulation tools, identify customer segments, and develop targeted go-to-market strategies for Australia's growing computational biology sector.
- Healthcare Investors & Venture Capitalists : Need comprehensive market analysis to evaluate investment opportunities, assess growth potential, and identify promising startups and companies in Australia's biosimulation ecosystem.
- Academic & Research Institutions : Require market data to justify funding requests, identify collaboration opportunities with industry, and align research initiatives with commercial applications in Australia's biotech landscape.
Key Companies in the Australia Biosimulation Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| SANOFI | France | Public Company | Pediatric and combination vaccines (polio, pertussis, Hib, hexavalent),Other vaccines (RSV, hepatitis A, typhoid, yellow fever, rabies),Immunology and inflammation therapies, |
| CERTARA | United States | Public Company | Biosimulation platforms (Simcyp, Phoenix, NLME, Pirana),Regulatory data and submission software (Pinnacle 21, GlobalSubmit, CoAuthor, Metadata Repository),Discovery and informatics solutions (Chemaxon suite, D360, design tools), |
| DASSAULT SYSTÈMES | France | Public Company | 3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA), |
| SCHRöDINGER, INC. | United States | Public Company | Software,Drug Discovery – Collaborations (e.g., Novartis),Drug Discovery – Internal Pipeline, |
| SIMULATIONS PLUS | United States | Public Company | PBPK/PKPD and biopharmaceutics software (GastroPlus, DDDPlus, MembranePlus),QSP and disease-systems platforms (DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, Thales),ADMET Predictor, MedChem Designer and discovery-oriented AI/ML tools, |
| PHYSIOMICS PLC | United Kingdom | Public Company | Oncology modeling & simulation (Virtual Tumour–centric consulting),Broader quantitative pharmacology & computational biology services,Personalized medicine technology and related analytics, |
| INSTEM PLC | United Kingdom | Private Company | Research study management software (discovery, preclinical, early clinical),Regulatory submission and SEND-compliant dataset solutions,In silico and data insights / predictive analytics, |
SANOFI
Sanofi is a French multinational pharmaceutical company founded in 1994 with 74,846 employees. As a public company, it operates globally in the development, manufacturing, and distribution of medicines and vaccines.
CERTARA
Certara is a United States-based public company founded in 2008 with 1,546 employees. It provides software and services for drug development, including modeling, simulation, and regulatory consulting.
DASSAULT SYSTÈMES
Dassault Systèmes is a French software company founded in 1981 with 25,724 employees. As a public company, it develops 3D design, simulation, and digital lifecycle management solutions for various industries.
SCHRöDINGER, INC.
Schrödinger, Inc. is a United States-based public company founded in 1990 with 850 employees. It provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.
SIMULATIONS PLUS
Simulations Plus is a United States-based public company founded in 1996 with 213 employees. It develops software for drug development, including pharmacokinetic and pharmacodynamic modeling and simulation.
PHYSIOMICS PLC
Physiomics PLC is a United Kingdom-based public company founded in 2001 with 10 employees. It specializes in computational biology and systems pharmacology for drug development.
INSTEM PLC
Instem PLC is a United Kingdom-based private company founded in 1969 with 510 employees. It provides software and services for data management and analysis in preclinical and clinical research.
Reasons to Buy this Report
- Market Size & Growth Data : Access precise valuation metrics for Australia's biosimulation market with detailed CAGR analysis, enabling accurate financial forecasting and investment planning for the 2026-2031 period.
- Competitive Landscape Intelligence : Understand Australia-specific market dynamics, key players, and competitive positioning to identify partnership opportunities and market entry strategies in this high-growth segment.
- Regulatory & Policy Insights : Gain clarity on Australia's regulatory environment, government support mechanisms, and policy drivers influencing biosimulation adoption among pharmaceutical and biotech organizations.
- Investment & Expansion Strategy : Leverage market projections and growth drivers to make informed decisions about R&D investments, facility expansion, and resource allocation in Australia's biosimulation sector.
- Technology Adoption Trends : Identify emerging technologies, application areas, and adoption patterns specific to Australia's pharmaceutical industry to align product development and marketing strategies effectively.
Frequently asked questions
What is the current size of Brazil's biosimulation market?
Brazil's biosimulation market is valued at USD 29.6 million in 2026 and is expected to grow to USD 46.3 million by 2031.
What is the projected growth rate for biosimulation in Brazil?
Brazil's biosimulation market is projected to grow at a compound annual growth rate (CAGR) of 16.2% from 2026 to 2031.
What factors are driving biosimulation adoption in Brazil?
Key drivers include Brazil's expanding biopharmaceutical industry, regulatory modernization, government support for precision medicine, and the need to reduce clinical trial costs and timelines.
How does Brazil's biosimulation market compare to Latin America?
Brazil represents a significant portion of the Latin American biosimulation market, with strong growth momentum driven by institutional investments and pharmaceutical sector expansion.
Which sectors in Brazil are adopting biosimulation technology?
Brazil's pharmaceutical companies, academic research institutions, contract research organizations (CROs), and government health agencies are increasingly adopting biosimulation for drug development and clinical research.
RESEARCH METHODOLOGY
This research study involved the extensive use of both primary and secondary sources. It involved the analysis of various factors affecting the industry to identify the segmentation types, industry trends, key players, the competitive landscape of market players, and key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies.
Secondary Research
This research study extensively utilized secondary sources, including directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, as well as white papers, annual reports, and companies' house documents. The secondary research aimed to gather and analyze information for a comprehensive and commercially focused study of the biosimulation market, encompassing technical aspects and market dynamics. It also facilitated the identification of key players, market classification, industry trends, geographical markets, and significant market-related developments. Additionally, a database of prominent industry leaders was compiled through secondary research.
Primary Research
In the primary research process, various supply-side and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, engineers, and related key executives from various companies and organizations operating in the biosimulation market. Primary sources from the demand side included personnel from pharmaceutical & biotechnology companies, contract research organizations, academic & research institutes, and regulatory bodies.
A breakdown of the primary respondents is provided below:
Note: Tiers are defined based on a company’s total revenue, as of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million. Other designations include sales managers, marketing managers, and product managers.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the biosimulation market was determined after data triangulation through the two approaches mentioned below. After the completion of each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.
Biosimulation Market : Top-Down and Bottom-Up Approach
Data Triangulation
The size of the biosimulation market was estimated through segmental extrapolation using the bottom-up approach. The methodology used is as follows: -
- Revenues for individual companies were gathered from public sources and databases.
- Shares of leading players in the biosimulation market were gathered from secondary sources to the extent available. In certain cases, shares of biosimulation businesses were ascertained after a detailed analysis of various parameters, including product portfolios, market positioning, selling price, and geographic reach & strength.
- Individual shares or revenue estimates were validated through interviews with experts.
- The total revenue in the biosimulation market was determined by extrapolating the market share data of major companies.
Market Definition
Biosimulation is a technology that employs computer-aided simulations to replicate and predict the dynamics of biological processes and systems. It uses modern computational power to analyze and model biological behavior through mathematical expressions. Biosimulation, often referred to as Computer-aided Drug Design (CADD), plays a critical role in various stages of drug discovery and development. Leveraging AI and machine learning, biosimulation enhances the evaluation of drug safety, efficacy, and interactions, ultimately streamlining clinical trial design and accelerating time-to-market for new therapeutics.
Key Stakeholders
- Clinical/Physician centers
- Biosimulation vendors
- Clinical research organizations
- Pharmaceutical/Biopharmaceutical companies
- Research & development (R&D) companies
- Business research and consulting service providers
- Medical research laboratories
- Academic medical centers/Universities/Hospitals
- Regulatory agencies
- Clinical researchers
- Accountable care organizations
- Investors and venture capitalists
Report Objectives
- To define, describe, and forecast the biosimulation market based on offering, phase of development, modality, application, therapeutic area, deployment mode, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall biosimulation market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments such as product launches & approvals, partnerships, agreements, and collaborations in the overall biosimulation market
- To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
- Company information
- Detailed analysis and profiling of additional market players (up to 5)
Regional Analysis
- Further breakdown of the Rest of Asia Pacific biosimulation market into Taiwan, New Zealand, Thailand, Singapore, Malaysia, and other countries
- Further breakdown of the Rest of Europe biosimulation market into Russia, Austria, Finland, Sweden, Turkey, Norway, Poland, Portugal, Romania, Denmark, and other countries
Get the Full Biosimulation Market Report
Full forecast, segment splits, and company analysis for all Biosimulation Market.
- US Biosimulation Market
- Canada Biosimulation Market
- Germany Biosimulation Market
- France Biosimulation Market
- UK Biosimulation Market
- Italy Biosimulation Market
- Spain Biosimulation Market
- China Biosimulation Market
- Japan Biosimulation Market
- India Biosimulation Market
- South Korea Biosimulation Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report